Managing scarlet fever

  title={Managing scarlet fever},
  author={Drug and Therapeutics Bulletin},
  journal={British Medical Journal},
### What you need to know Scarlet fever is an infection caused by toxin producing strains of Streptococcus pyogenes (also known as group A streptococcus, or GAS). It was associated with high levels of morbidity and mortality when epidemics were common in the 18th and 19th centuries in Europe and the USA.1 Although the disease nearly disappeared during the 20th century, several countries, including the UK, have recently experienced a re-emergence of scarlet fever.123 In this article, we discuss… Expand


Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study.
England is experiencing an unprecedented rise in scarlet fever with the highest incidence for nearly 50 years, and reasons for this escalation are unclear and identifying these remains a public health priority. Expand
Re-emergence of scarlet fever: old players return?
Typing, molecular characterization, and often genome sequencing of scarlet fever GAS isolates have been performed in several cases and brought light upon the genetic determinants of GAS andScarlet fever, and it is likely that environmental and host-related factors are also involved. Expand
Epidemiology of Severe Streptococcus pyogenes Disease in Europe
A high incidence of severe S. pyogenes disease in Europe is confirmed through a European Union FP-5-funded program (Strep-EURO), and seasonal patterns of infection showed remarkable congruence between countries. Expand
Genome analysis following a national increase in Scarlet Fever in England 2014
There is no evidence that the increased number of scarlet fever cases was a strain-specific or known mobile element specific phenomenon, as the increase in SF cases was associated with multiple lineages of GAS. Expand
Invasive Group A Streptococcal Disease
Early institution of intravenous immunoglobulin therapy should be considered in cases of toxic shock syndrome and severe invasive infection, including necrotizing fasciitis, and clindamycin is an important adjunctive antibacterial because of its anti-toxin effects and excellent tissue penetration. Expand
Household transmission of invasive group A Streptococcus infections in England: a population-based study, 2009, 2011 to 2013
While a dramatically increased risk of infection was noted in all household contacts, increased risk was greatest for mother-neonate pairs and couples aged 75 and over, suggesting targeted prophylaxis could be considered. Expand
Increase in scarlet fever notifications in the United Kingdom, 2013/2014.
  • R. Guy, C. Williams, +11 authors T. Lamagni
  • Medicine
  • Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
  • 2014
Increases in scarlet fever above usual seasonal levels are currently being seen across the United Kingdom and the potential for this to signal a population increase in invasive group A streptococcal disease is essential. Expand
Transfer of scarlet fever-associated elements into the group A Streptococcus M1T1 clone
The presence of mobile genetic elements associated with the expansion of emm12 scarlet fever clones1011 in the M1T1 genomic background should trigger heightened public health awareness for the global dissemination of these genetic elements. Expand
Scarlet Fever Upsurge in England and Molecular-Genetic Analysis in North-West London, 2014
Molecular epidemiologic investigation of Streptococcus pyogenes infections in North-West London highlighted increased emm4 and emm3 infections coincident with the upsurge in scarlet fever notifications in spring 2014. Expand
  • G. Worrall
  • Medicine
  • Canadian family physician Medecin de famille canadien
  • 2011
Preservation of the tonsils, an important source of immunoglobulins, in this state of altered immunity is most essential, apart from the need to avoid the unnecessary risks of tonsillectomy so vividly expressed by Dr Beckenham. Expand